Dermapharm Holding SE (DE:DMP)
XETRA:DMP
Want to see DE:DMP full AI Analyst Report?
Top Page
Dermapharm Holding SE
(XETRA:DMP)
Select Model
Select Model
Rating:68Neutral
Price Target:
€50.00
▲(8.23% Upside)
Action:Reiterated
Date:05/15/26
The score is driven primarily by solid financial performance (re-accelerating revenue, strong margins, and healthy free cash flow) but tempered by elevated leverage and margin volatility. Technicals add support via a strong uptrend and positive MACD, while valuation is reasonable with a moderate dividend yield.
Positive Factors
Vertically integrated business model
Dermapharm's integrated model—R&D, in‑licensing, commercial brands plus contract manufacturing and OTC—creates multiple durable revenue channels. Vertical integration supports margin capture, capacity leverage and cross‑selling, reducing reliance on a single product or channel.
Negative Factors
Elevated leverage
Debt remains meaningfully elevated despite improvement, increasing interest and refinancing risk. High leverage constrains strategic flexibility, limits capacity for large acquisitions or capex without further funding, and heightens vulnerability to cyclical or regulatory shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertically integrated business model
Dermapharm's integrated model—R&D, in‑licensing, commercial brands plus contract manufacturing and OTC—creates multiple durable revenue channels. Vertical integration supports margin capture, capacity leverage and cross‑selling, reducing reliance on a single product or channel.
Read all positive factors
Dermapharm Holding SE (DMP) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€2.35B
Dividend Yield2.34%
Average Volume (3M)18.50K
Price to Earnings (P/E)17.7
Beta (1Y)0.47
Revenue Growth-1.36%
EPS Growth39.24%
CountryDE
Employees3,610
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.69
Shares Outstanding49,540,810
10 Day Avg. Volume17,993
30 Day Avg. Volume18,498
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)3.05
Price to Sales (P/S)1.82
P/FCF Ratio15.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.00Price Target Upside12.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.67
Revenue Forecast (FY)€1.20B
Dermapharm Holding SE Business Overview & Revenue Model
Company Description
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmace...
How the Company Makes Money
Dermapharm makes money primarily by selling pharmaceutical and health products and by providing manufacturing-related services. Its key revenue streams typically include: (1) Prescription pharmaceuticals: revenue from selling branded generics and ...
Dermapharm Holding SE Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
56
Neutral
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.17B | 1.16B | 1.18B | 1.14B | 1.02B | 942.91M |
| Gross Profit | 499.33M | 391.71M | 767.07M | 719.16M | 660.83M | 620.69M |
| EBITDA | 332.91M | 314.31M | 320.91M | 265.55M | 329.81M | 358.10M |
| Net Income | 144.21M | 132.41M | 113.79M | 62.37M | 134.24M | 209.58M |
Balance Sheet | ||||||
| Total Assets | 2.27B | 2.20B | 2.08B | 2.16B | 1.41B | 1.41B |
| Cash, Cash Equivalents and Short-Term Investments | 254.00M | 203.41M | 121.71M | 159.54M | 161.36M | 172.06M |
| Total Debt | 1.04B | 1.05B | 979.61M | 1.08B | 516.45M | 580.30M |
| Total Liabilities | 1.54B | 1.50B | 1.47B | 1.62B | 880.34M | 907.13M |
| Stockholders Equity | 738.86M | 694.38M | 604.42M | 539.21M | 531.59M | 497.32M |
Cash Flow | ||||||
| Free Cash Flow | 198.33M | 139.39M | 163.14M | 177.88M | 249.52M | 189.16M |
| Operating Cash Flow | 242.22M | 181.51M | 201.38M | 219.42M | 288.53M | 250.37M |
| Investing Cash Flow | -101.62M | -110.03M | -29.61M | -415.43M | -99.01M | -129.35M |
| Financing Cash Flow | -28.63M | 13.32M | -209.17M | 204.54M | -199.77M | -80.98M |
Dermapharm Holding SE Technical Analysis
Neutral
46.20
Price Trends
47.14
Positive
43.25
Positive
39.13
Positive
Market Momentum
0.15
Positive
49.33
Neutral
59.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DMP, the sentiment is Neutral. The current price of 46.2 is below the 20-day moving average (MA) of 47.93, below the 50-day MA of 47.14, and above the 200-day MA of 39.13, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 49.33 is Neutral, neither overbought nor oversold. The STOCH value of 59.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:DMP.
Dermapharm Holding SE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | €57.85B | 22.84 | 8.77% | 1.82% | -1.69% | -10.15% | |
68 Neutral | €2.35B | 17.73 | 21.44% | 2.34% | -1.36% | 39.24% | |
60 Neutral | €321.88M | 22.19 | 2.69% | ― | 10.99% | -5.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €346.39M | -5.35 | -16.02% | ― | -36.17% | 48.61% |
* Healthcare Sector Average
DE:DMP
Dermapharm Holding SE
47.50
13.80
40.94%
DE:B8FK
Biofrontera
2.35
-0.02
-0.84%
DE:MRK
Merck KGaA
133.05
26.24
24.57%
DE:ILM1
Medios AG
12.62
0.52
4.30%
DE:PHH2
PAUL HARTMANN AG
213.00
-24.41
-10.28%
DE:FYB
Formycon AG
19.60
-6.70
-25.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.